logo
#

Latest news with #VoxCellBioInnovation

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

National Post

time31-07-2025

  • Business
  • National Post

Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development

Article content LAVAL, Québec — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation ('VoxCell'), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. Article content This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. Article content 'We're proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,' Article content said Steve Mason, Co-Chief Operating Officer at Altasciences. Article content 'This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.' Article content VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies. Article content 'Our mission has always been to make drug screening more human-relevant and predictive,' Article content said Karolina Valente, CEO of VoxCell BioInnovation. Article content 'Altasciences shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.' Article content The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications. Article content This partnership represents a shared vision: to transform early-stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide. Article content About Altasciences Article content Altasciences Article content preclinical Article content and Article content clinical pharmacology Article content studies, including Article content formulation, manufacturing, and analytical services Article content . For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include Article content , Article content clinical pharmacology and proof of concept Article content , Article content bioanalysis Article content , program management, Article content research support Article content , medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Article content . Article content About VoxCell BioInnovation Article content VoxCell BioInnovation Article content is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology research and drug development. Article content VoxCell develop 3D bioprinted vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for predictive, physiologically relevant research. Using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, they produce complex tissue models that mirror patient biopsy samples in structure and function. Article content Article content Article content Article content Contacts Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store